Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
07:44am, Wednesday, 13'th Mar 2024
— Company ends 2023 with approximately $123.6 million in cash and investments. Combined with gross proceeds from $108.9 million private placement in January, Solid has anticipated cash runway into 2
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
11:20am, Sunday, 18'th Feb 2024
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to
Another Huge Buffett Purchase Highlights Recent Insider Buying
08:53am, Monday, 12'th Feb 2024
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
Joe Lewis, billionaire owner of Tottenham Hotspur football club, pleads guilty to insider trading
11:29am, Wednesday, 24'th Jan 2024
British billionaire Joe Lewis, who owns the Tottenham Hotspur football club, has pleaded guilty to insider trading charges in New York, after prosecutors had charged him with sharing secret stock tips
More Big Warren Buffett Purchases Highlight Recent Insider Buying
10:49am, Saturday, 20'th Jan 2024
The number of notable insider purchases in mid-January may have been somewhat small, but a couple from the Oracle of Omaha made headlines.
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up
12:31pm, Wednesday, 17'th Jan 2024
Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
11:01pm, Tuesday, 16'th Jan 2024
IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs mark
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
08:00am, Tuesday, 16'th Jan 2024
– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision g
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why
12:02pm, Monday, 15'th Jan 2024
The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.
Solid Biosciences Announces $109 Million Private Placement
07:09am, Monday, 08'th Jan 2024
CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, toda
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up
06:46am, Friday, 08'th Dec 2023
Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.
Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND
09:46am, Thursday, 16'th Nov 2023
Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.
Are Gene Therapy Stocks The Market's Next Big Winners?
08:06am, Monday, 25'th Sep 2023
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD
Solid Biosciences to Present at JMP Securities Life Sciences Conference
04:05pm, Monday, 08'th May 2023
CHARLESTOWN, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced
Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference
08:00am, Thursday, 13'th Apr 2023
CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announ
